title: Erythropoietin is approved for the treatment of anemia associated with renal failure, chemotherapy, preoperative anemia, and human immunodeficiency virus disease.
authors.forename: Sheila
authors.initials: S
authors.lastname: Savur
authors.forename: Maurizio
authors.initials: M
authors.lastname: Bonacini
authors.forename: Natalie
authors.initials: N
authors.lastname: Bzowej
authors.forename: Robert
authors.initials: R
authors.lastname: Gish
authors.forename: Adil
authors.initials: A
authors.lastname: Wakil
authors.forename: Robert
authors.initials: R
authors.lastname: Osorio
mesh_terms: D000328:Adult; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D004921:Erythropoietin / Q000627:therapeutic use*; D006400:Hematocrit; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D008875:Middle Aged; D051437:Renal Insufficiency / Q000097:blood / Q000150:complications*; D016896:Treatment Outcome
chemical_list: D004921:Erythropoietin